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Broncholveolar lavage (BAL), an important tool for evaluating interstitial lung diseases (ILDs), has limited utility 
due to its invasiveness and the difficulty of performing it in clinically contraindicated patients. We compared BAL 
with the induced sputum (IS) technique to analyse cells and T lymphocytes in patients with sarcoidosis (SA) and 
non-granulomatous ILD (NG-ILD). Pulmonary function tests and BAL were performed by conventional methods. 
IS induction was done 20 set after inhalation of 3.5% saline with an ultrasonic nebulizer. Giemsa-stained cytopreps 
were differentially counted. T lymphocyte subsets were analysed by flow activated cell sorter (FACS). Patients with 
NC-ILD had impaired total lung capacity (TLC). Transbronchial biopsy demonstrated lung fibrosis in NG-ILD 
and non-caseating granuloma in SA. The differential cell count in both groups demonstrated a significantly lower 
percentage of neutrophils and a significantly higher percentage of macrophages in BAL than in IS. The IS samples 
of patients with SA were significantly richer in metachromatic cells and eosinophils, but had a lower percentage of 
lymphocytes, compared to the BAL samples. The profiles of T cell subsets showed the same pattern, in both 
samples, in both groups. A CD4/CD8 ratio of 2.5 or greater had a sensitivity of 100% and a specificity of 81.2%, 
with a positive predictive value of 8 1.2% to distinguish SA from NG-ILD. IS is an effective non-invasive technique 
to identify CD4+ inflammation which distinguishes sarcoidosis from other NG-ILDs. 
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Introduction 
The technical availability of the fiberoptic bronchoscope 
has facilitated the development of the bronchoalveolar 
lavage (BAL) procedure which is useful for the collection of 
cells and secretions from the lower respiratory tract (1). 
Sampling of the inflammatory response, in patients with 
interstitial lung diseases (ILDs), has been useful in 
diagnosing specific conditions, staging the extent of diseases 
and, in some cases, predicting response to treatment (2,3). 
Although this technique is an essentially non-invasive 
procedure when applied under proper selection guidelines, 
and bears minimal risk to the patient, it is not suitable for 
patients suffering from other diseases that contraindicate 
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bronchoscopy. Moreover, there are frequently problems 
with patient compliance. The only totally non-invasive 
method for directly studying inflammatory processes in the 
lung is the examination of sputum. 
Several studies have illustrated the usefulness of sputum 
cell counts to investigate the pathogenesis, pathophysiology 
and treatment of asthma (4,5). Fahy et al. conducted a 
comparison of samples collected by sputum induction and 
bronchoscopy from asthmatic and healthy subjects (6). 
Only a few studies have used induced sputum (IS) in 
subjects suspected of occupational exposures: eosinophil 
counts have been performed in the IS of asthmatic 
isocyanates-sensitized subjects (7) and the frequency of 
bronchial dysplasia has been investigated in sputum of past 
exposed miners (8). Teschler et al. studied the relevance of 
asbestos bodies in spontaneous sputum production (9). 
However, the method employing IS in the evaluation of 
patients suffering from interstitial lung diseases (ILDs) in 
comparison to the evaluation performed by BAL has not 
been reported before. 
The main objectives of this study were to compare the 
cell counts and the type of inflammation between samples 
obtained by BAL and IS in patients with ILDs. 
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Methods 
SUBJECTS 
bronchoscope wedged into a sub-segmental bronchus of the 
middle lobe or lingula. The cells were recovered by gentle 
aspiration. 
The study group consisted of 30 patients who underwent 
bronchoscopy, including BAL, and transbronchial biopsy 
for diagnostic purposes. None of them had been receiving 
medications before being enrolled. They were divided into 
two groups: 
Group I consisted of 16 patients with several non- 
granulomatous interstitial lung diseases (NG-ILDs, 14 men 
and two women, mean age 5s~ 57f 14 years). Four 
patients had cryptogenic fibrosing alveolitis (CFA) and two 
had collagen diseases with lung involvement (rheumatoid 
arthritis and dermatomyositis). They had diffuse reticular 
infiltraton which was demonstrated on chest X-ray, while a 
transbronchial biopsy showed evidence of different degrees 
of interstitial fibrosis. One patient had increased eosino- 
philic infiltration in transbronchial biopsy and her chest X- 
rays showed peripheral infiltrates, mostly in the left lung, 
both of which are compatible with eosinophilic pneumonia 
(EP). The three patients with silicosis had been working in 
the cutting process of producing natural and artificial 
marble stone for at least 10 yr, and six others worked as 
hard-metal grinders for around 13 yr. All of them showed 
marked fibrosis on trans-bronchial biopsies (TBB). Ten out 
of 16 patients were smokers. 
Group II consisted of 14 patients with sarcoidosis (SA, 
four men and 10 women, mean age i SD 48 f 10 years) who 
were diagnosed by clinical and roentgenological evaluation. 
Twelve out of 14 had a positive transbrochial biopsy 
showing non-caseating granuloma. Patient 13 showed 
mediastinal and paratracheal symmetrical enlargment of 
lymphonodes on computerized tomography (CT) and had a 
positive gallium scan. The skin biopsy of patient 14 showed 
subcutaneous lymphonodes and non-caseating granulomas 
compatible with sarcoidosis. According to the chest X-ray 
findings, seven patients were classified as being in Stage I, 
one in Stage I-II, three in Stage II and three in Stage II-III. 
None of them were smokers. 
PROTOCOL 
The study involved at least three visits to the department. 
Physical examination, pulmonary function test and obtain- 
ing informed consent to bronchoscopy, were carried out at 
the first visit. BAL and TBB were performed at the second 
visit (at least 1 week after the first visit). Sputum induction 
was carried out during the third visit (at least 2 weeks after 
the second one). 
PREPARATION OF BRONCHOALVEOLAR 
CELLS 
The recovered fluid was collected into specimen traps, 
filtered through sterile gauze and centrifuged at 400 x g for 
15 min at 4°C. The pellet was washed three times with cold 
phosphate-buffered saline (PBS; Biological Industries, Beit 
Haemek, Israel) and the cells were adjusted to a final 
concentration of lo6 cells ml-’ in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 2% fetal 
calf serum (Biological Industries). One hundred microlitres 
of this suspension was loaded into cuvettes of a cytocen- 
trifuge (Cytospin; Shandon, Southern Products Ltd, 
Runcorn, Cheshire, U.K.). The slides were spun at 1000 
rpm for 5 min and the fluid blotters were removed. After 
the slides were dried in air, a differential count was 
performed on Giemsa (Merck, Darmstard, Germany) 
stained preparations by counting a minimum of 500 cells. 
Metachromatic cells were identified by toluidine blue 
staining. 
SPIROMETRY 
The spirometry was performed by a Masterlab spirometer 
(Masterlab E. Jaeger, Wurzburg, Germany). The measure- 
ment was performed using standard protocols according to 
American Thoracic Society (ATS) guidelines. The best of 
three consecutive measurements was chosen. 
SPUTUM INDUCTION 
Sputum induction was performed with an aerosol of 
hypertonic saline generated by a DeVilbiss Aerosonic 
Ultrasonic Nebulizer 5OOOD/50001 (DeVilbiss-Health Care 
Corporation Somerset, PA, U.S.A.) with an output of 
0.5 ml min-’ and particle size of less than 5 microns 
aerodynamic mass median diameter, using a slightly 
modified method of Pin et al. (10). Subjects inhaled 
nebulized 3.5% saline for up to 20 set by ultrasonic 
nebulizer, through a mouth-piece without a valve or 
noseclip. Ten minutes after the start of nebulization and 
every 5 min thereafter, subjects were asked to rinse their 
mouths with normal saline to minimize contamination with 
saliva. The patient was encouraged to cough, and 
expectorated sputum into a sterile plastic container. The 
nebulization was stopped after 20 min, or earlier if the 
sputum sample was of sufficiently good quality. 
BRONCHOALVEOLAR LAVAGE (BAL) 
SPUTUM EXAMINATION 
BAL was performed using a flexible fiberoptic video 
bronchoscope (Pentax, Japan). Subjects were premeditated 
with pethidin 50 mg and atropin 0.5 mg, and the airways 
were anesthetized by inhalation of 4% xylocaine. Boluses of 
50 ml of 0.9% saline previously warmed to 37°C and up to 
a total volume of 150-200 ml, were instilled with the 
The method of sputum examination described by Popov 
et al. was used (11) with some modifications. Sputum was 
processed as soon as possible within 2 h. Sputum was 
poured onto a petri dish, and all portions with little or no 
non-squamous epithelial cells considered to originate from 
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the lower respiratory tract, were selected under an inverted 
microscope and placed in an eppendorf tube, whereupon 
the weight was recorded. 
Dithiothreitol (DTT- Sputalysin, Calbiochem Corp., San 
Diego, CA, U.S.A) was freshly prepared in a dilution of 
1:lO with distilled water according to the manufacturers 
instructions. The volume added was twice the recorded 
weight of the plugs and it was mixed mechanically with the 
sputum by aspiration in and out of a pipette about 20 times 
to ensure mixing. The sample was then placed in a shaking 
water bath at 37°C for 15 min to ensure complete 
homogenization. To stop the effect of DTT, the suspension 
was further diluted with PBS to a volume equal to the 
sputum plus DTT. The cell suspension was filtered through 
52 ,nm nylon gauze (BNSH Thompson, Scarborough; 
Ontario, Canada) to remove debris and mucus, and the 
volume of the filtrate was recorded. The total cell count was 
measured using a haemocytometer (Neubauer chamber, 
Sigma Chemicals, St Louis, MO, U.S.A.). The filtered cell 
suspension was diluted with RPM1 supplemented with FCS 
to achieve a concentration of 103/pl. One drop was placed 
in each cytocentrifuge cup already in place in a Shandon III 
cytocentrifuge (Shandon Southern Instruments, Sewickley, 
PA, U.S.A.) and cytospins were prepared at 1000 RPM1 
supplemented with 10% FCS (Biological Industries, Beit 
Haemek, Israel) for 5 min. Separate cytospin slides were 
stained by Giemsa. The cell counts were performed by 
scanning the cytospins, starting at the top left corner in an 
undulating manner from top to bottom while moving 
across the slide using high power (x 500) magnification. 
Two hundred non-squamous cells were counted and the 
results were expressed as a percentage of the total non- 
squamous cell count. 
EVALUATION OF PHENOTYPE OF LAVAGE 
AND SPUTUM CELLS 
Flow cytometric analysis was performed on a dual FACS 
440 equipped with an Art and Kr laser (Becton-Dickinson, 
Mountain View, CA, U.S.A.). Data were collected and 
analysed using the Consort VAX and Disp4 and Disp2D 
programs (Becton-Dickinson). The information was col- 
lected on a logarithmic scale. The selection of the 
lymphocyte population was based on side scatter and 
expression of CD 45. Lymphocytic subsets were identified 
by monoclonal antibodies as follows: CD3: total T cells; 
CD4: T helper cells; and CDS: T suppressor-cytotoxic cells. 
Monoclonal antibodies were directly conjugated to either 
phycoerythrin (RDI) or fluorescein isothiocyanate (FITC). 
Cells were incubated for 10 min with Epics Coulter Q-Prep 
and read either immediately or after 24 h. 
STATISTICAL METHODS 
Since the data were not normally distributed, the non- 
parametric Wilcoxon test was used to compare the 
differences in differential cell counts and cell subsets. The 
chi-square test was used to compare differences between sex 
and smoking habits. Multiple correlation was used to 
compare identity between numeric values of CD4/CD8 
ratio in BAL and sputum. Fisher correlation was used to 
find the predictive value of CD4/CD8 ratio higher than 2.5 
to discriminate between SA and NG-ILD. Probability 
values ~0.05 were considered as being significant. 
Results 
The demographic, histological and functional findings in all 
groups are shown in Tables 1 and 2. Patients with 
sarcoidosis were younger than patients with other ILDs 
(48 i 9 yr vs. 57-J 14 yr, P= 0.02). There was a sex 
difference between group I and group II patients 
(P= 0.04). Values of TLC capacity were significantly 
reduced in group I compared to group II (81_+ 11% vs. 
93+ 15%, respectively, P=O.O13). 
The percentage of lavage fluid recovered was 58.2 i 8.2% 
and the average total cells recovered was higher among the 
smokers (14 f4.5 x lo6 cells ml-’ ) compared to the non- 
smokers (7.13+ 1.5 x lo6 cells ml-‘). Differential counts 
and T cell subsets of all patients according to the type of 
disease (as described in the study population) are listed in 
Tables 3 and 4. The percentage of alveolar macrophages in 
the BAL was significantly higher compared to the 
percentage of macrophages in the sputum for both groups 
(group I: 70.6+22 % vs. 34.9116%, P=O.O009; group II: 
60.9+18 % vs. 32.0118.2%, P=O*OOl), while the 
percentage of neutrophils in the BAL was significantly 
lower compared to that of sputum (group I: 7.0,5.9% vs. 
49.1+13.7%; P=O.O004; group II: 2.5+4.1% vs. 
51.3+18%, P=O.OOl). There were no significant differ- 
ences between percent of lymphocytes in group I 
(19.6*19.7% vs. 14.7$8.7%, P=O.43), but the percent 
of lymphocytes in BAL was significantly higher compared 
to sputum in the group of patients with sarcoidosis 
(34& 15.6% vs. 10,6*7*6%, P=O.OOl). Finally, the 
percents of metachromatic cells were higher in sputum 
compared to BAL in sarcoidosis (4.2i 4.1% vs. 
0.9&2.1%, P=O.O13). 
The results of the analysis of T cell subsets are 
summarized in Tables 5 and 6. The number of the T cell 
populations analysed were greater in the BAL than in the 
IS, but the CD4/CD8 ratio showed no significant differ- 
ences between BAL and sputum in both groups (1 . 1 + 0.9% 
vs. 1.8*1.5%, P=O.l in NG-ILD; 5.9*2.7% in BAL vs. 
7.2 f 5.7% in SA, P = 0.10). In both groups taken together, 
there was a good correlation between the CD4+ and CD8+ 
populations in BAL and IS compared to the total 
population of CD3+ lymphocytes (v = 0.6266; P = 0.00021 
in CD4/CD3 ratio and I = 0.8804, P = 0.00014 in CD8/CD3 
ratio, Figs 1 and 2) in each individual patient. All values of 
CD4/CD8 ratios higher than 2.5 were found to be more 
frequent in IS samples obtained from patients with 
sarcoidosis than with NG-ILDs (P = 0.0025). We compared 
the CD4/CD8 ratio of IS lymphocytes with those of BAL 
and, by doing so, we found the predictive value of IS in 
order to detect CD4+ alveolitis in patients with proved 
sarcoidosis: there was a sensitivity of loo%, a specificity of 
81.2% and a positive predictive value of 81.2%. 
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TABLE 1. Demographic, clinical and physiological parameters of non-granulomatous interstitial lung disease (NG-ILD) 
patients 
No Sex Age@-) Smoking Disease TBB DLCO TLC 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Mean + SD 
M 
F 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
M 
85 
60 
39 
79 
64 
40 
50 -. 
31 
47 
61 
61 
46 
63 
62 
58 
66 
57 + 14 
Yes CFA Fibrosis 
No RA Fibrosis 
No CFA Fibrosis 
Yes CFA Fibrosis 
Yes CFA Fibrosis 
No DM Fibrosis 
No EP Fibrosis 
Yes SI Fibrosis 
Yes SI Fibrosis 
Yes HMD Fibrosis 
No HMD Fibrosis 
Yes HMD Fibrosis 
Yes HMD Fibrosis 
No HMD Fibrosis 
Yes SI Fibrosis 
Yes HMD Fibrosis 
80 77 
77 80 
72 81 
41 66 
59 64 
70 70 
ND ND 
94 100 
100 82 
85 89 
98 82 
76 92 
59 100 
94 94 
58 70 
70 70 
765 16 81 + 11 
F: female; M: male; DLCO: diffusion lung capacity CO % predicted; TLC: total lung capacity % predicted;CFA: crytogenic 
fibrosing alveolitis; RA: rheumatoid arthritis; DM: dermatomyositis; EP: eosinophilic pneumonia; 
SI: silicosis; HMD: hard metal diseases; ND: not done. 
TABLE 2. Demographic, clinical and physiological parameters of patients with sarcoidosis 
No Sex Age (v-s> Smoking TBB Staging DLCO TLC 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Mean +_ SD 
F 
F 
M 
F 
F 
F 
F 
M 
M 
F 
M 
F 
F 
F 
48 
58 
40 
35 
45 
50 
42 
42 
41 
49 
45 
70 
60 
42 
48 + 9 
No NCG Stage II-III 
No NCG Stage I 
No NCG Stage I 
No NCG Stage I-II 
No NCG Stage I 
No NCG Stage I 
No NCG Stage I 
No NCG Stage I 
No NCG Stage I 
No NCG Stage II 
No NCG Stage II 
No NCG Stage II-III 
No ND Stage II 
No NCG* Stage II-III 
38 80 
85 85 
113 93 
73 83 
59 111 
75 79 
88 105 
97 82 
80 88 
87 116 
57 80 
58 83 
87 125 
68 97 
76+_ 19 93 &- 15 
F: female; M: male; NCG: non-caseating granuloma; DLCO: diffusion lung capacity CO, % predicted; TLC: total lung 
capacity, %predicted; ND = not done. 
*in skin. 
Discussion sputum can be considered a sensitive and non-invasive tool 
to differentiate CD4+ alveolitis from others kinds of 
In this study, we compared the cellular components of lymphocytic disorders. 
samples obtained by BAL and IS in patients with ILDs. Our first objective in the current study was to directly 
Our data support the view that the T cell sub-populations compare the cellular constituents of IS and BAL samples 
present in the samples and recovered by IS correlates well obtained by bronchoscopy in patients with ILDs. We found 
to those recovered by BAL. Moreover, the analysis of that IS samples contained a significantly higher percentage 
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TABLE 3. Differential counts (%) in bronchoalveolar lavage (BAL) and induced sputum (IS) cells in non-granulomatous 
interstitial disease (NG ILD)* 
BAL IS 
No Total yield^ MAC LYM PMN EOS METH Total yield MAC LYM PMN EOS METH 
1 10 63.8 29.4 5.6 1.2 0 1.0 51.2 7.3 41.0 0.5 0 
2 8 58.2 28.4 12.4 1.0 0 2.5 35.0 2.0 62.0 1.0 0 
3 7 86.2 0.6 12.6 0,4 0.2 1.5 32.4 25.0 50.0 1.0 2 
4 9 79.6 19.8 0.6 0 0 1.3 66.0 13.0 19.0 2.0 0 
5 11 86.0 11.6 1.2 0 1.2 2.5 58.0 18.0 24.0 0 0 
6 8 97.6 2.0 0.4 0 0 1.5 42.5 8.5 49.0 0 0 
7 8 62.8 28.2 0.5 16.0 2.4 1.0 37.2 11.0 47.0 2.4 2.4 
8 19 23.2 57.8 10.4 4.8 3.8 2.0 23.5 31.0 45.5 0 0 
9 13 72.6 16.2 11.0 0 0.4 1.5 27.8 9.0 59.6 1.8 1.8 
10 18 20.0 68.0 4.6 5.6 1.8 2.2 33.0 10.0 56.0 1.0 1.0 
11 9 79.0 2.0 13.6 4.8 0.6 1.8 22.0 26.0 52.0 0 0 
12 15 89.4 3.8 2.0 4.6 0.2 1.9 26.8 28.0 45.2 0 0 
13 11 82.4 9.2 8.4 0 0 2.0 22.1 11.3 66.6 0 0 
14 10 88.0 3.8 8.0 0.2 0 1.6 38.5 19.5 42.5 0 0 
15 20 74.2 23.2 1.6 0 1.0 1.5 20.0 10.0 70.0 0 0 
16 22 67.0 10.4 20.0 1.6 1.0 2.0 33.0 10.0 57.0 2.0 0 
Mean 12.3 70.6"" 19.6# 7.03 2.5 1.3 1.7 34.9 14.7 49.1 0.7 0.5 
SD 4.8 22.0 19.7 5.9 4.1 2.3 0.5 13.6 8.7 13.7 0.9 1.2 
Median 10.5 76.6 13.8 6.X 0.7 0.5 1.5 33.0 10.6 49.5 0.2 0 
“Differential counts were performed by counting 500 cells in Giemsa-stained cytopreps and T cells subsets were identified by 
FACS as described in Material and Methods. MAC: macrophages; LYM: lymphocytes; PMN: polymorphonuclears; EOS, 
eosinophils; METH: metachromatic cells. h Total yield: x lo6 cells. 
= **P=O.O009 between % macrophages in BAL and IS; ii P 
between % neutrophils in BAL and IS. 
0.43 between % lymphocytes in BAL and IS; r P= 0.0004 
of neutrophils and a lower percentage of macrophages 
compared to those recovered by BAL. These findings are 
similar to those found for normal subjects and asthmatics 
(6) and suggest that the portion of IS derived from the lungs 
arises predominantly from neutrophil-rich secretions (12), 
mainly recovered from large airways, while the BAL 
technique samples the distal alveolar space which consists 
mainly of macrophages (13). The percentages of metachro- 
matic cells and eosinophils were found to be higher in IS 
samples compared to the BAL ones only in the group of 
patients suffering from sarcoidosis. These data provide 
evidence of the infiltration of those cells into the bronchial 
mucosa, as supported by studies of others who have showed 
that patients with sarcoidosis have an increased frequency 
of bronchial hyper-reactivity and signs of mast cell 
activation as compared to normal volunteers (14). The 
percentages of lymphocytes were similar in the IS and BAL 
samples in the group of patients with NG-ILD, but the 
samples from BAL showed a significantly higher percentage 
of lymphocytes than the IS ones, in patients with 
sarcoidosis. These findings are the result of there being a 
different source of the samples: BAL describes samples of 
cells and secretion from the alveolar and bronchial air 
spaces while IS samples mainly upper and mid-airways. 
However, it is already known that only lymphocytosis in 
BAL is not discriminative for sarcoidosis as there are 
numerous other diseases (e.g., non-sarcoid ILD, multiple 
pulmonary infections, non-infectious identified pulmonary 
inflammation and a variety of neoplasms involving the lung 
and bronchial hyper-reactivity) that can result in increased 
lymphocytes in BAL fluid specimens (15). 
It had been reported that sarcoidosis is a disease mediated 
by the accumulation of activated CD4+ lymphocytes (16 
18). Some reports show the CD4/CD8 ratio to be helpful in 
distinguishing it from other diseases (19). It was in this 
context that we analysed and compared the sub-populations 
of T lymphocytes in samples obtained by BAL and by IS in 
both groups (Tables 5 and 6). We found that although the 
percentage of total CD3+, CD4+ and CD8+ cells analysed 
are lower in samples from IS compared to BAL, the 
proportion of the subsets correlate well in both samples. 
The upper and lower normal values for the CD4/CD8 
ratio of T lymphocytes in BAL were found to be 1 to 2.5, 
respectively (13): we found that a CD4jCD8 ratio of 2.5 or 
greater has a high positive predictive value in distinguishing 
sarcoidosis from NG-ILD. This finding contributes more 
data to the ongoing debate between some groups of 
investigators regarding the predictive value of the CD4/ 
CD8 ratio: our results support the groups which endorse 
that a high ratio of CD4/CDX has a high specificity 
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TABLE 4. Differential counts (%) in bronchoalveolar lavage (BAL) and induced sputum (IS) cells in sarcoidosis (SA)* 
No 
BAL IS 
Total yield^ MAC LYM PMN EOS METH Total yield MAC LYM PMN EOS METH 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Mean 
SD 
Media 
6 
8 
7 
9 
5 
8 
9 
10 
6 
8 
5 
7 
6 
6 
1.6 
7 
87.4 
59.8 
81.8 
59.7 
85.0 
61.4 
41.4 
53.0 
71.6 
53.2 
35.6 
32.0 
76.4 
53.6 
60.9”” 
18 
59 
10.8 1.8 0 0 
35.6 4.6 0 0 
15.6 2.6 0 0.5 
38.4 0.8 0.6 0.2 
14.6 0.2 0 0.8 
36.0 0 1.8 0 
58.6 0 0 0 
45.6 1.2 1.2 O-8 
27.6 0 0 0.8 
45.8 0 1.0 0 
48.8 7.4 0 8.2 
49.0 12.0 1.0 1.0 
11.6 10.6 1.4 0 
41.6 1 3.4 1.0 
34.2# 2.5: 0.67” O-9? 
15.6 4.0 0.99 2.1 
37.2 0.9 0.1 0.2 
3.1 77.0 9.0 10.0 4.0 0 
1.9 12.0 22.6 64.5 0.6 0.3 
2.0 23.6 9.0 64.6 2.4 0.4 
1.6 16.0 20.0 60.0 0 4.0 
1.0 43.2 6.4 48.2 0 2.2 
2.0 50.0 13.0 26.0 6.0 5.0 
2.3 37.0 10.0 41.0 0 12.0 
1.7 32.5 6.5 48.0 0.5 12.5 
1.8 51.5 5.0 35.0 1.5 7.5 
1.5 19.5 9.0 65.0 0.5 6.0 
0.9 16.5 27.5 50.0 2.5 3.5 
1.1 30.0 2.0 66.0 0 2.0 
1.6 23.0 2.0 73.0 0 3.0 
1.2 17.0 7.5 67.0 8.5 0 
1.5 32.0 10.6 51.3 1.8 4.2 
0.4 18.2 7.6 18.1 2.5 4.1 
1.6 26.8 9.0 55.0 0.5 3.2 
*Differential counts were performed by counting 500 cells in Giemsa stained cytopreps. Total yield: x lo6 cells. 
**P = 0.001 between % macrophages in BAL and IS; #P = 0.001 between % lymphocytes in BAL and IS; IP = 0.001 
between % neutrophils in BAL and IS; §P = 0.08 between % eosinophils in BAL and IS; TP = 0.013 between % 
metachromatic cells in BAL and IS. 
TABLE 5. T cell subsets of cells recovered by bronchoalveolar lavage (BAL) and induced sputum (IS) in non-granulomatous 
interstitial lung disease (NG-ILD)* 
BAL IS 
No CD3 CD4 CD8 CD4/CD8 CD4/CE3 CD8/CD3 CD3 CD4 CD8 CD4/CD8 CD4/CD3 CD8/CD3 
1 98 47.0 51.0 0.92 0.47 0.52 42.0 26.0 16.0 0.8 0.61 0.38 
2 66 40.0 26.0 1.5 0.6 0.39 74.0 50.0 24.0 2.1 0.67 0.32 
3 85 52.0 33.0 1.6 0.61 0.38 30.0 22.4 6.6 3.5 0.74 0.22 
4 83 41.5 41.4 1.0 0.5 0.49 65.0 45.0 20.0 2.3 0.69 0.30 
5 86 29.2 50.7 0.58 0.34 0.59 34.0 17.2 16.0 1.1 0.50 0.47 
6 67 38.4 35.4 1.19 0.57 0.53 85.0 45.0 30.0 1.5 0.52 0.35 
7 87 38.0 44.3 0.86 0.44 0.51 72-O 45.0 23.0 1.9 0.62 0.31 
8 88 21.7 66.4 0.3 0.25 0.75 85.0 10.8 50.0 0.2 0.12 0.58 
9 97 51.5 64.0 0.5 0.32 0.66 60.0 27.0 28.4 0.9 0.45 0.47 
10 95 11.0 75.8 0.15 0.11 0.79 61.9 13.6 48.3 0.3 0.21 0.78 
11 86 64.4 21.2 2.1 0.75 0.25 57.0 37.0 24.0 1.5 0.65 0.42 
12 90 63.4 23.8 2.8 0.70 0.26 60.0 27.0 28.4 6.2 0.45 0.47 
13 92 54.8 29.4 1.86 0.59 0.32 73.0 43.6 23.5 2.1 0.60 0.32 
14 48 13.5 34.3 0.39 0.28 0.58 41.0 17.0 24.0 0.7 0.41 0.58 
15 85 23.0 61.8 0.37 0.27 0.55 89.0 39.6 49.5 0.8 0.44 0.55 
16 83 53.2 29.4 1.8 0.64 0.26 59.0 43.3 15.6 2.9 0.73 0.26 
Mean 83.4** 48.9” 42.9” 1.19 0.44 0.49 61.7 31.8 26.7 1.8 0.47 0.46 
SD 13.0 16.4 16.8 0.9 0.21 0.19 17.9 13.1 12.6 1.5 0.18 0.15 
*T cell subsets were analysed by FACS as described in Material and Methods. **P= 0.004 between % CD3 in BAL and IS; 
#P= 0.07 between % CD4 in BAL and IS. §P= 0.0004 between % CD8 in BAL and IS; yP= 0.1 between CD4/CD8 in BAL 
and IS. 
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TABLE 6. T cell subsets of cells recovered by bronchoalveolar lavage (BAL) and induced sputum (IS) in sarcoidosis (SA)* 
BAL IS 
No CD3 CD4 CD8 CD4/CD8 CD4/CD3 CD8/CD3 CD3 CD4 CD8 CD4/CD8 CD4/CD3 CD8/CD3 
1 86 61.6 16.9 3.6 0.72 0.19 72.0 60.0 11.2 5.4 0.83 0.15 
2 96 84.2 11.8 7.1 0.87 0.12 90.0 80.9 8.6 9.4 0.89 0.09 
3 96 73.0 22.0 3.3 0.76 0.22 91.0 64.8 26.1 2.5 0.71 0.28 
4 67 22.9 13.1 2.9 0.34 0.19 86.0 82.0 14.0 5.8 0.95 0.16 
5 92 78.6 11.2 7.0 0.85 0.12 26.0 20.4 2.4 8.5 0.78 0.09 
6 63 82.8 10.2 8.1 0.89 0.11 39.5 32.5 7.0 4.6 0.82 0.17 
7 89 69.5 16.1 4.3 0.78 0.18 23.8 20.0 3.8 5.0 0.84 0.15 
8 96 88.9 6.6 13.5 0.92 0.06 56.3 42.9 11,2 3.8 0.76 o-19 
9 96 76.7 14.1 5.4 0.79 0.14 76.3 56.3 12.7 4.4 0.73 0.16 
10 99 76.3 18.7 4.1 0.77 0.18 79.0 73.0 6.0 12.7 0.92 0.07 
11 96 80.8 Il.0 7.3 0.84 0.11 44.8 37.7 7.1 5.3 0.84 0.15 
12 73 38.4 10.2 3.76 0.52 0.83 54.3 45.1 9.2 4.9 0.83 0.16 
13 93 79.4 14.0 5.67 0.85 0.77 80.1 61.7 18.4 3.4 0.77 0.23 
14 84 13.0 8.0 6.5 0.15 0.78 94.0 74.0 3.5 25.0 0.78 0.04 
Mean 87.5** 66.1” 13.1” 5.98 0.17 0.28 65.2 53.6 10.0 7.2 0.8 0.14 
SD 11.7 23.9 4.2 2.7 0.25 0.27 24.2 20.9 6.4 5.7 0.07 0.05 
*T cell subsets were analysed by FACS as described in Material and Methods. **P= 0.0076 between % CD3 in BAL and IS; 
"P= 0.18 between % CD in BAL and IS. §P = 0.09 between % CD8 in BAL and IS; TP = 0.50 between CD4/CD8 ratio cells in 
BAL and IS. 
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FIG. 1. Correlation between CD4jCD3 in ratio 
bronchoalveolar lavage (BAL) VS. induced sputum (IS). 
rz0.6266, P=O.O0021. 
(> 90%) and a sensitivity of 50-60% (19,21) compared to 
lung biopsies. This result is opposed to those who contend 
that there is a high variability in the CD4/CD8 ratio among 
sarcoid patients (22). 
The central aim of this paper was to show that the 
lymphocytic population of bronchi and alveoli can be 
compared. It is known that the population of lymphocytes 
in BAL is a dynamic balance between entry and exit of 
these cells from other compartments of the lung (23). It is 
reasonable to assume that there is traffic of CD4+lympho- 
cytes from the bronchial lamina propia to the bronchoal- 
veolar space in sarcoidosis. 
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FIG. 2. Correlation between CDS/CD4 ratio in 
bronchoalveolar lavage (BAL) VS. induced sputum (IS). 
r=0.8804. P=O.O0014. 
It is known that Sarcoidosis is a chronic inflammatory 
disorder that is characterized by the pronounced infiltration 
of CD4+ lymphocytes in the lung and that there is 
involvement of other extrapulmonary organs (16-l 8). 
Moreover, the fact that epithelioid granulomatosis in 
endobronchial biopsies was also found in patients with 
sarcoidosis (24) supports the contention that CD4+ 
accumulation in sputum can sometimes be a local effect, 
and not a product of traffic from alveolar lymphocytes in 
some patients. 
The updated criteria for identifying active sarcoidosis are 
based on clinical symptoms, chest X-ray/CT scan, gallium 
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scan, pulmonary function tests, BAL with transbronchial 
biopsy and serum markers (24). We propose herein another 
marker that can be added to those used to diagnose 
sarcoidosis. 
BAL, which has been used in recent years for the 
diagnosis of ILD, is a procedure that requires special 
expertise, cannot be done on all patients and requires 
willingness on the part of those who can undergo it. In 
contrast, IS far easier to carry out, and is non-invasive and 
less expensive than BAL. 
In conclusion, analysis of T cell subsets by IS can be as 
helpful as BAL analysis in diagnosing sarcoidosis in 
patients with clinical contraindications for undergoing 
bronchoscopy or when, for any other reasons, tissue 
samples are not available. 
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